Vertiv Holdings ( NYSE: VRT) on Monday was rated Outperform in new research coverage by analysts at investment firm William ...

Jed Dorsheimer, William Blair analyst, joins 'The Exchange' to discuss Tesla's chip deal with Samsung and what it means for ...

Fintel reports that on July 30, 2025, William Blair downgraded their outlook for CyberArk Software (NasdaqGS:CYBR) from Outperform to Market Perform. Analyst Price Forecast Suggests 4.72% Upside As of ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

William Blair analyst Matt Larew maintained a Hold rating on Amedisys today. The company’s shares closed yesterday at $97.52. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing ...

William Blair cheers Tesla-Samsung chip deal but keeps TSLA at Hold, citing auto margin woes and valuation concerns.

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Mastercard eased concerns about a potential slowdown in consumer spending after beating Wall Street estimates for ...

Move over Humira, Skyrizi and Rinvoq are expected to beat the former megablockbuster’s peak sales by the end of this year.

In addition, The Allstate Corporation (NYSE:ALL) is taking advantage of a far better auto loss environment and employing ...

Starbucks CEO Brian Niccol says his company will rebound from lackluster earnings with its “green apron service” plan. Here’s ...

Onvansertib combined with standard care showed up to 49% confirmed ORR in RAS-mutated colorectal cancer, with early signs of ...